AstraZeneca Rebrands to Vaxzevria

Australia’s medical regulator, the Therapeutic Goods Administration (TGA) has approved the rebranding of the AstraZeneca COVID-19 vaccine to Vaxzevria.

According to TGA, the rebranding would follow the naming convention in European countries and Canada.

“This name change will also help facilitate international recognition for Australians who have been vaccinated with the AstraZeneca vaccine,” said TGA. 

TGA said it hoped the change in name would prevent confusion in the future and allow vaccinated citizens to travel abroad once international travel opens again. 

AstraZeneca said both the old name and Vaxzevria would be still seen together for some time but they assured the public that they are the same and are recognized by the WHO.

“AstraZeneca’s COVID-19 vaccine is the same product wherever it is made,” said AstraZeneca.

© Fourth Estate® — All Rights Reserved.
This material may not be published, broadcast, rewritten or redistributed.